Clinical Trial Update: Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluating the use of nilotinib and imatinib after donor stem cell transplant in patients with acute lymphoblastic leukemia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Childhood Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia
• Chronic Myeloid Leukemia Accelerated Phase
• Chronic Myeloid Leukemia Blast Crisis
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Gleevec (Imatinib)
• Tasigna (nilotinib)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-05-15